Patent intelligence · US
US 10344027
Compositions and methods for inhibiting kinases
Compositions and methods for inhibiting kinases
Patent details — US 10344027
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 9, 2019
- Expiration
- Jul 4, 2039
- Applicant
- Inhibikase Therapeutics, Inc.
- Claims
- 8
- CPC classes
- A61K, A61K2300/00, A61K31/506, A61K45/06
Quick answer
US 10344027 (Compositions and methods for inhibiting kinases) is held by Inhibikase Therapeutics, Inc.. Status: granted. Granted Jul 9, 2019. Expires Jul 4, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Inhibikase Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K2300/00, A61K31/506, A61K45/06, A61P, A61P31/04
More from Inhibikase Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11725005
Compositions and methods for inhibiting kinases
granted -
US 11407747
Compositions and methods for inhibiting kinases
granted -
US 10906896
Compositions and methods for inhibiting kinases
granted -
US 10316031
Compositions and methods for inhibiting kinases
granted -
US 10118923
Compositions and methods for inhibiting kinases
granted -
US 9907796
Methods of treating tumoral diseases, or bacterial or viral infections
granted -
US 9828370
Compositions and methods for inhibiting kinases
granted
Frequently asked questions
What is US patent 10344027?
US 10344027 (Compositions and methods for inhibiting kinases) is held by Inhibikase Therapeutics, Inc.. Status: granted. Granted Jul 9, 2019. Expires Jul 4, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10344027?
Inhibikase Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 10344027 expire?
Our index shows an expiration date of Jul 4, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.